Collaboration - August 17, 2022
Genmab and BioNTech expand global strategic collaboration
The two companies have announced an expansion of their collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients. Under the expansion, Genmab and BioNTech will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint development […]
Clinical Trials - April 20, 2022
Genmab announces phase 1/2 trial results
Genmab and AbbVie have announced topline results from the first cohort of the EPCORE NHL-1 clinical trial evaluating epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic therapy, including 38.9 percent who received prior treatment with […]
Biotech Business - April 13, 2021
Genmab’s BLA accepted for priority review
Genmab and Seagen have announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) seeking accelerated approval for tisotumab vedotin. This BLA requests FDA approval of tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, […]
Clinical Trials - September 22, 2020
Genmab and Seattle Genetics present new data
Genmab and Seattle Genetics has presented data from the innovaTV 204 phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer. Patients had previously received a doublet chemotherapy and, if eligible, bevacizumab as first-line therapy. Results from the trial showed a 24 percent confirmed objective […]
Agreement - October 3, 2019
Genmab enters into agreement with Tempus
Genmab has entered into a strategic collaboration agreement with Tempus, a privately-owned technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The multi-year collaboration will combine Tempus’ sequencing capabilities and platform of integrated clinical and molecular data with Genmab’s translational, biomarker and target discovery expertise, they state. The companies will […]
New Market - October 2, 2017
Approval for Genmab’s DARZALEX in Japan
The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the use of DARZALEX (daratumumab) in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma. D ARZALEX is being developed under an August 2012 agreement in which Genmab granted Janssen Biotech, Inc. an […]
